Melanoma

Brent Hanks, MD, PhD, is the Discussant at the Clinical Science Symposium “Systems Biology Approaches to Immunotherapy Response and Toxicity” presentation entitled ‘Rise of the Machines: AI in Predicting Immunotherapy Outcomes’.

April Salama, MD, director of Duke Cancer Institute's Melanoma disease group, is on the ASCO Annual Meeting's Scientific Program Committee on Melanoma and Skin Cancers. She is also a Poster Discussant for Melanoma/Skin Cancers —“Characterizing Long Term Outcomes in Metastatic Melanoma in 2020.” 

ABSTRACTS

*Duke authors are bolded

Multiomics profiling of longitudinal melanoma specimens unravels molecular mechanisms of resistance to sequential targeted and cancer immunotherapies.
SESSION
Publication Only: Melanoma/Skin Cancers
AUTHOR(S)
Jinho Lee, Marilyne Labrie, Gen Yong, Todd Camp, Hongli Ma, Megan Grout, Wei Xu, Georgia Beasley, Lynn Mara Schuchter, Suzanne McGettigan, Donald M. O'Rourke, Meenhard Herlyn, Christopher L. Corless, Gordon B. Mills, Gao Zhang
ABSTRACT e22015